TOMI Environmental Solutions, a global company specialising in disinfection and decontamination solutions, has announced a collaboration with Cellares to integrate its SteraMist ionized Hydrogen Peroxide (iHP) technology into a revolutionary new cell therapy manufacturing solution, the Cell Shuttle, designed and produced by Cellares.
The Cellares Cell Shuttle is a breakthrough in automated cell therapy manufacturing, offering end-to-end automation and reducing inefficiencies.
We continue to seek out and build strong partnerships with leading life science manufacturers where there is a need for all the advantages of SteraMist iHP disinfection technology
- Elissa Shane, TOMI COO
This system enables fully automated production of cell therapies for up to 16 different patients simultaneously, a significant increase in yield compared to traditional manufacturing methods.
Due to the critical importance of maintaining a sterile environment within the confined spaces of the Cell Shuttle, Cellares selected TOMI's patented iHP decontamination technology. The SteraMist iHP technology ensures comprehensive decontamination with its small micron particles, offering advantages in efficacy and safety over other commercially available decontamination methods.
The partnership
TOMI and Cellares began their partnership in 2021 and are now in the final stages of iHP Cell Shuttle prototypes. TOMI has developed a new sleek, clean, compliant, and efficient system for integration into the Cell Shuttle. These systems are designed to be compact while maintaining all industry standards that SteraMist iHP technology represents.
“Our collaboration with TOMI and SteraMist iHP technology has been instrumental in bringing effective decontamination to the Cell Shuttle,” said Daniele Malleo, PhD, VP of Research & Development at Cellares. “We are confident that our design, coupled with the SteraMist iHP decontamination, will set the standard for cell-therapy manufacturing in the industry.”
“We are incredibly excited that Cellares is working with our team to achieve seamless integration of our technology into their groundbreaking Cell Shuttle. It has been a pleasure collaborating with their research and development team to develop a tailor-made SteraMist iHP system, designed to meet their requirements and be offered alongside their product,” Elissa Shane, TOMI’s COO, said.
Shane further explained: “We continue to seek out and build strong partnerships with leading life science manufacturers where there is a need for all the advantages of SteraMist iHP disinfection technology.”